Dipexium Pharmaceuticals Inc  

(Public, NASDAQ:DPRX)   Watch this stock  
Find more results for Jack D. Duffy
+0.02 (0.17%)
Dec 1 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.59 - 12.00
52 week 10.00 - 17.10
Open 11.98
Vol / Avg. 14,575.00/34,180.00
Mkt cap 123.10M
P/E     -
Div/yield     -
EPS -1.83
Shares 10.30M
Beta     -
Inst. own 30%
Nov 16, 2015
Q3 2015 Dipexium Pharmaceuticals Inc Earnings Call
Nov 16, 2015
Q3 2015 Dipexium Pharmaceuticals Inc Earnings Release
Sep 9, 2015
Dipexium Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
Sep 9, 2015
Dipexium Pharmaceuticals Inc at FBR Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.06% -86.95%
Return on average equity -53.43% -93.16%
Employees 5 -
CDP Score - -


61 Broadway Rm 1905
NEW YORK, NY 10006-2747
United States - Map
+1-212-2692834 (Phone)
+1-845-8183588 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Dipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex, a topical antibiotic. Locilex is a chemically synthesized, 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its mechanism of action kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). Locilex affects only the area to which it is applied. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a clinical study in patients with Mild or Moderate DFI. It has conducted microbiology studies that highlight the sensitivity of resistant bacteria, including methicillin-resistant staphylococcour aureour (MRSA), vancomycin-resistant enterococcour (VRE), extended-spectrum b-lactamase (ESBL) and multi-drug resistant (or MDR) bacteria, to pexiganan, the active pharmaceutical ingredient (API) in Locilex.

Officers and directors

Robert J. DeLuccia Executive Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
David P. Luci Esq. President, Chief Executive Officer, Secretary, Director
Age: 48
Bio & Compensation  - Reuters
Robert G. Shawah CPA. Chief Accounting Officer, Treasurer
Age: 48
Bio & Compensation  - Reuters
David Garrett Vice President, Finance and Corporate Development, IR Contact Officer
Age: 39
Bio & Compensation  - Reuters
Jack Hugh Dean Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters
Michael E. Duffy Esq. Independent Director
Age: 45
Bio & Compensation  - Reuters
Thomas L. Harrison Independent Director
Age: 67
Bio & Compensation  - Reuters
Barry Kagan Independent Director
Age: 57
Bio & Compensation  - Reuters
William J. McSherry Jr., Esq. Independent Director
Age: 66
Bio & Compensation  - Reuters